Investment Thesis
Aclaris is a clinical-stage pharmaceutical company with severe fundamental deterioration, evidenced by a 58.2% revenue collapse, massive operating losses of -$76.4M, and negative free cash flow of -$47.2M. Despite maintaining adequate liquidity and manageable debt levels, the company is burning cash at an unsustainable rate with no clear path to profitability, making it a high-risk investment for fundamentals-focused investors.
Strengths
- Strong liquidity position with current ratio of 3.36x and $20.0M cash reserves
- Conservative leverage with debt-to-equity of only 0.10x, reducing financial distress risk
- Positive gross margin of 41.4% indicates product viability when revenue is generated
Risks
- Catastrophic 58.2% year-over-year revenue decline suggests loss of major contracts or failed clinical programs
- Operating losses of $76.4M with negative FCF of $47.2M indicates unsustainable cash burn at current trajectory
- Severely negative profitability ratios (operating margin -975.9%, net margin -829.6%) demonstrate fundamental unprofitability with no near-term improvement visible
- R&D-heavy business model typical of biotech requires continued capital infusion with uncertain outcomes
Key Metrics to Watch
- Quarterly revenue trends and pipeline advancement to confirm stabilization vs. further decline
- Monthly cash burn rate and cash runway to assess solvency timeline
- Clinical trial progress and regulatory milestones for lead candidates to evaluate future revenue potential
Financial Metrics
Revenue
7.8M
Net Income
-64.9M
EPS (Diluted)
$-0.53
Free Cash Flow
-47.2M
Total Assets
160.5M
Cash
20.0M
Profitability Ratios
Gross Margin
41.4%
Operating Margin
-975.9%
Net Margin
-829.6%
ROE
-63.0%
ROA
-40.5%
FCF Margin
-603.4%
Balance Sheet & Liquidity
Current Ratio
3.36x
Quick Ratio
3.36x
Debt/Equity
0.10x
Debt/Assets
35.8%
Interest Coverage
N/A
Long-term Debt
10.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T11:20:11.105166 |
Data as of: 2025-12-31 |
Powered by Claude AI